Publications
107
Citations
1,639
Est. group size
~3
Recurring co-author estimate
Active years
55
Publishing since 1972
Typically publishes in teams of ~15 · 0% small-team papers (≤3 authors) · across 28 venues
- Modelling approaches for estimating vaccine effectiveness of consecutive SARS-CoV-2 variant sublineages in the absence of study-specific genetic sequencing data, VEBIS hospital network, Europe, 2023/24
PLoS ONE · 2026
- Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025
Eurosurveillance · 2025
- COVID‐19 Vaccine Effectiveness Against Hospitalizations and Severe Outcomes in Kosovo, 2022–2024: A Test‐Negative Case–Control Study
Influenza and Other Respiratory Viruses · 2025
- Effectiveness of the XBB.1.5 COVID‐19 Vaccines Against SARS‐CoV‐2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024
Influenza and Other Respiratory Viruses · 2025
- Evaluation of European severe acute respiratory infection (SARI) surveillance, 27 European countries, 2022/23
Eurosurveillance · 2025
- Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025
Eurosurveillance · 2025
- Vaccine effectiveness against influenza A in older adults and the effect of chronic conditions: results from the I-MOVE and VEBIS multicentre European hospital case–control studies, 2015/16–2023/24
BMC Medicine · 2025
- COVID‐19 Vaccine Effectiveness Against Hospitalization in Older Adults, VEBIS Hospital Network, Europe, September 2024–May 2025
Influenza and Other Respiratory Viruses · 2025
- Modelling approaches for estimating vaccine effectiveness of consecutive SARS-CoV-2 variant sublineages in the absence of study-specific genetic sequencing data, VEBIS hospital network, Europe, 2023/24
medRxiv · 2025
- Author response for "Effectiveness of the XBB.1.5 COVID‐19 Vaccines Against SARS‐CoV‐2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024"
2025
- COVID-19 vaccine effectiveness against hospitalizations and severe outcomes in Kosovo, 2022-2024: a test negative case–control study
2025
- Comparing Outcomes of Covid-19 and Influenza Among Hospitalized Adults in Five Countries and Areas in the European Severe Acute Respiratory Infection Vaccine Effectiveness (Eurosave) Network, 2021–2024
SSRN Electronic Journal · 2025
- Vaccine effectiveness against influenza A in older adults and the effect of chronic conditions: Results from the I-MOVE and VEBIS multicentre European hospital case–control studies, 2015/16–2023/24
Research Square · 2025
- COVID-19 vaccine effectiveness against hospitalisation in older adults, VEBIS hospital network, Europe, September 2024--May 2025
2025
- Out-of-pocket costs, time burden, and caregiver quality of life associated with pediatric medically attended respiratory syncytial virus illnesses
Cost Effectiveness and Resource Allocation · 2025
- Eurosurveillance×13
- Influenza and Other Respiratory Viruses×6
- Zenodo (CERN European Organization for Nuclear Research)×5
- PEDIATRICS×3
- BMC Public Health×3
- Katherine Adams
Medicine · University of Michigan
- Adam S. Lauring
Medicine · University of Michigan
- Mark W. Tenforde
Medicine · University of Michigan
- Diya Surie
Medicine · University of Michigan
- Sara Y. Tartof
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile